What is MyLife Technologies?
Founded in 2012, MyLife Technologies specializes in the development of Micro-Needle Array Patches (MNAPs). By utilizing ceramic materials, the company offers a sophisticated alternative to traditional hypodermic needles, facilitating precise, painless, and efficient drug delivery. The company's market position is defined by its focus on the intersection of material science and pharmaceutical logistics, addressing the global demand for safer, more accessible immunization and medication delivery methods. As the firm moves beyond its initial research and development phase, it is increasingly focused on scaling its manufacturing capabilities to meet enterprise-level requirements for global healthcare providers.
How much funding has MyLife Technologies raised?
MyLife Technologies has raised a total of $4.3M across 2 funding rounds:
Unspecified
$340K
Series A
$4M
Unspecified (2018): $340K with participation from Uniiq
Series A (2021): $4M led by Fare Capital and SAL Beheer
Key Investors in MyLife Technologies
Fare Capital
A venture capital firm focused on supporting high-growth technology companies with significant market disruption potential.
SAL Beheer
An investment entity specializing in long-term capital support for innovative Dutch enterprises within the life sciences and technology sectors.
Uniiq
A regional investment fund that provides early-stage capital to startups in the South Holland province, focusing on proof-of-concept and commercialization.
What's next for MyLife Technologies?
The recent capital allocation is earmarked for the industrialization of the company's ceramic patch platform. Moving forward, MyLife Technologies is expected to prioritize regulatory milestones and strategic partnerships with pharmaceutical manufacturers to integrate its MNAP technology into existing drug pipelines. By leveraging its recent financing, the company aims to transition from a specialized technology developer to a high-volume supplier, effectively disrupting the conventional injection market. Future growth will likely hinge on the successful clinical validation of its patches for high-demand vaccines, potentially setting a new standard for patient-centric drug administration.
See full MyLife Technologies company page
